NEOG heads into its October 1 earnings release with short interest rising sharply, options traders skewing bullish, and a stock that just shed nearly 9% in a week from levels that were already up roughly 95% year-to-date.
Short sellers have turned notably more aggressive in the run-up. Short interest climbed 14% over the past week to 5.3% of the free float, and is up 45% over the past month, the fastest build in the dataset's recent history. That adds up to roughly 11.6 million shares short, with days to cover running at 4.5. Despite the acceleration in positioning, the borrow market remains easy: availability is well above 1,000%, meaning there are more than ten shares available to lend for every one already borrowed, and the cost to borrow is only 0.56%, barely above its recent floor. Short sellers are building, but without any squeeze pressure to keep them honest. The stock itself fell 7.2% on September 29 alone, extending a weekly decline of nearly 9%, even as it sits on a 95% gain for 2026.
Options traders are telling a different story from the short book. Call positioning is unusually dominant relative to recent history: the put/call ratio is 0.28, well below its 20-day average of 0.38, placing it roughly 1.2 standard deviations on the bullish side. That divergence between rising short interest and call-heavy options flow is one of the more charged setups heading into the print.
The analyst picture offers modest support with some caution baked in. Piper Sandler upgraded NEOG to Overweight in late August, raising its target to $14, a move that followed a post-earnings rally of 28% on July 30. Guggenheim maintains a Buy rating with a $12 target. The consensus sits at buy across three analysts, with a mean target of $13.33, fractionally above the current price of $12.73. Bulls point to Neogen's positioning in food and animal safety diagnostics, a market with structural regulatory tailwinds, and the operational boost from recent acquisitions. Bears focus on decelerating sales growth and margin pressure from production costs and supply chain friction. At 35x trailing earnings and 18x EV/EBITDA, the valuation leaves limited room for a miss after such a strong re-rating.
One ownership development worth noting: Neuberger Berman added 8.8 million shares in the period to August 31, making it the second-largest institutional holder at 7.6% of shares. That is a substantial build from a fundamental manager. On the other side of the ledger, Norges Bank cut its stake from 6.8% to 4.2%, and the original Vanguard Group entity exited entirely before Vanguard's two separate portfolio vehicles re-established positions. Insider activity in the window shows mostly compensation-related grants and tax withholding transactions, with the CEO's only open-market purchase a token 370 shares in August. None of the recent insider flow reads as a high-conviction signal. All 13D/G positions are as last disclosed around the 5% threshold; holders falling below that level may not file again.
Wikipedia page views for NEOG registered a z-score of 2.8 against its own 90-day history as of September 23, placing retail attention well above its recent norm. This is a measure of attention, not a revenue indicator, but the spike aligns with the stock's dramatic year-to-date run and the proximity of the earnings date.
The print will test whether the operational improvement that drove July's 28% single-day gain has continued at a pace that justifies the stock trading at roughly twice where it started the year, with short sellers now more committed than at any point in recent months.
See the live data behind this article on ORTEX.
Open NEOG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
